

원저

The Study of NF- κ B(P50) Suppression mechanism with main Component of Bee Venom and Melittin on Human Synoviocyte

Kwon Soon-jung and Song Ho-sueb

College of Traditional Korean Medicine, Kyung Won University

Abstract

Melittin, cationic 26-amino acid, is the principal component of the bee venom (BV) which has been used for treatment of inflammatory disease such as arthritis rheumatism. NF- κ B is activated by subsequent release of inhibitory I κ B via activation of a multisubunit I κ B kinase (IKK). We previously found that melittin binds to the sulfhydryl group of p50, a subunit of NF- κ B. Since sulfhydryl group is present in kinase domain of IKK α and IKK β , melittin could modify IKK activity by protein-protein interaction. We therefore examined effect of melittin on IKK activities in sodium nitroprusside (SNP)-stimulated synoviocyte obtained from RA patients. Melittin suppressed the SNP-induced release of I κ B resulting in inhibition of DNA binding activity of NF- κ B and NF- κ B-dependent luciferase activity. Consistent with the inhibitory effect on NF- κ B activation, IKK α and IKK β activities were also suppressed by melittin. Surface plasmon resonance analysis realized that melittin binds to IKK α (K $_d$ = 1.34 $\times 10^{-9}$ M) and IKK β (K $_d$ = 1.01 $\times 10^{-9}$ M). Inhibition of IKK α and IKK β resulted in reduction of the SNP-induced production of inflammatory mediators NO and PGE $_2$ generation. The inhibitory effect of melittin on the IKKs activities, binding affinity of melittin to IKKs, and NO and PGE $_2$ generation were blocked by addition of reducing agents dithiothreitol and glutathione. In addition, melittin did not show inhibitory effect in the transfected Synoviocytes with plasmid carrying dominant negative mutant IKK α (C178A) and IKK β (C179A). These results demonstrate that melittin directly binds to sulfhydryl group of IKKs resulting in I κ B release, thereby inhibits activation of NF- κ B and expression of genes involving in the inflammatory responses.

Key words : Bee Venom, Melittin, I κ B kinase, NF- κ B, synoviocyte, NO, PGE $_2$

• Acceptance : 2005. 3. 2. • Adjustment : 2005. 3. 12. • Adoption : 2005. 3. 17.

• Corresponding author : Song Ho-sueb, Sonpa-gu(district) Sonpa-dong Seoul Korea, Kyung Won University Seoul Hospital, Acupuncture and Moxibustion Department
Tel. 82-2-425-3456 E-mail : hssong70@kyungwon.ac.kr

I. Introduction

Bee venom (BV) Acupuncture has been used to relieve pain and to treat inflammatory diseases such as rheumatoid arthritis (RA) in humans¹⁾ and experimental animals²⁾. BV contains melittin, a 26 amino acid peptide, forms an amphipathic helix with a highly charged carboxyl terminus of protein³⁾. We previously found that melittin inhibited NF- κ B activation by prevention of p50 translocation through by the protein (p50)-protein (BV or melittin) interaction through modification of sulfhydryl group of p50⁴⁾.

Structural data of IKK subunits reveal that cysteine residues are present in the kinase domain of IKK α and IKK β , and some of them located at functionally important sites (Cys-179) such as activation of T loop and the catalytic site⁵⁻⁶⁾. P50 also possesses a critical cycteine residue (Cys-62) at the N-terminal region of its DNA-binding domain⁷⁾. In several studies, potent inhibitors of NF- κ B activation have showed to interact with a specific cysteine residue of the IKK catalytic subunits or p50 subunit of NF- κ B resulting in target modified inactivation of NF- κ B⁵⁻⁷⁾. Moreover, this interaction was reversed by thiol-modifying agents, and expression of mutant IKK α , IKK β and p50, in which cycteine residues were replaced with other amino acids; alanine (IKK) or serine (p50) render the cells to become resistant to inhibitory effect of these inhibitors in NF- κ B activation⁵⁻⁷⁾, suggesting that cysteine in the proteins involving NF- κ B signal can be targets of these compounds.

In the present study, we investigated whether BV or melittin could bind with

sulfhydryl group of p50 and IKKs resulted in the inhibition of NF- κ B activity, I κ B release via target disruption of IKK by protein-protein (IKK-melittin) interaction and SNP-induced production of inflammatory mediators such as NO in synoviocyte obtained from RA patients were focused.

II. Materials and Methods

Goat polyclonal antibody to p50 (1:500), p65 (1:500), I κ B α (1:500), phospho-I κ B (1:200), I κ B (1:500), mouse polyclonal antibody to iNOS (1:50) and all of the secondary antibodies used in Western blot analysis were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). T4 polynucleotide kinase obtained was from Promega (Madison, WI). Poly (dIdC), horseradish peroxidase-labeled donkey anti-rabbit second antibody, and the ECL detection reagent were obtained from Amersham Pharmacia Biotech (Centennial Ave, NJ, USA). Reagents for SDS-polyacrylamide gel electrophoresis were from Bio-Rad (Alfred Nobel Drive Hercules, CA, USA). SNP, Griess reagent, monoclonal anti- β -actin antibody, and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide (MTT) and melittin, a component of BV were purchased from Sigma-Aldrich (St. Louis, MO, USA). All other reagents were also purchased from Sigma-Aldrich unless otherwise stated. BV was purchased from You-Miel BV Ltd (Hwasoon, Korea). The compositions are followings: melittin (45-50%), apamin (2.5-3%), MCD peptide (1-2%), PLA2 (12%), Lyso PLA (1%), Histidine (1-1.5%), Minimine (2-3%), 6pp lipids (4-5%).

III. Synoviocyte culture

Synovial tissues were obtained, with consent, from nine RA patients who were undergoing total knee replacement or arthroscopic synovectomy. From these samples, three cell lines were studied. To avoid the effect of steroids on the synovial cells, the patients were instructed to cease steroid medication for 2 months before the operation. All patients satisfied the 1987 revised diagnostic criteria of the American College of Rheumatology (31). Synovial tissues were minced and treated for 4 hr with 4 mg/ml collagenase (type I; Worthington Biochemical, Freehold, NJ, USA) in DMEM at 37°C in 5% carbon dioxide. Dissociated cells were plated in DMEM supplemented with 10% fetal bovine serum (Gibco Life Technologies, Rockville, MD, USA), penicillin (100 U/ml) and streptomycin (100 mg/ml). Cells were used between the third and fifth passages

IV. Determination of nitric oxide

Cells were grown in 24-well plates and then incubated with or without SNP (200 nM) in the absence or presence of various concentrations of BV (0.5, 1, 5 μ g/ml), or melittin (5, 10 μ g/ml) for 72 hr. The nitrite accumulation in the supernatant was assessed by Griess reaction (32). Each 100 μ l of culture supernatant was mixed with an equal volume of Griess reagent (0.1% N (1-naphthyl)-ethylenediamine, 1% sulfanilamide in 5% phosphoric acid) and incubated at room

temperature for 10 min. The absorbance at 550 nm was measured in an automated microplate reader, and a series of known concentrations of sodium nitrite was used as a standard.

V. Western blot analysis

Cells were homogenized with lysis buffer [50 mM Tris pH 8.0, 150 mM NaCl, 0.02% sodium azide, 0.2% SDS, 1 mM PMFS, 10 ml/ml aprotinin, 1% igapal 630 (Sigma Chem. Co.), 10 mM NaF, 0.5 mM EDTA, 0.1 mM EGTA and 0.5% sodium deoxycholate], and centrifuged at 23,000 g for 1 hr. Equal amount of proteins (80 μ g) were separated on a SDS/12%-polyacrylamide gel, and then transferred to a nitrocellulose membrane (Hybond ECL, Amersham Pharmacia Biotech Inc., Piscataway, NJ). Blots were blocked for 2 hr at room temperature with 5% (w/v) non-fat dried milk in Tris-buffered saline [10 mM Tris (pH 8.0) and 150 mM NaCl] solution containing 0.05% tween-20. The membrane was incubated for 4 hr at room temperature with specific antibodies: rabbit polyclonal antibodies against p50, p65, I κ B α , I κ B β (1:500) and phospho-I κ B α (1:200) (Santa Cruz, CA, USA Santa Cruz Biotechnology Inc.). The blot was then incubated with the corresponding conjugated anti-rabbit immunoglobulin G-horseradish peroxidase (Santa Cruz Biotechnology Inc.). Immunoreactive proteins were detected with the ECL western blotting detection system. The relative density of the protein bands was scanned by densitometry using MyImage (SLB, Seoul, Korea), and quantified by Labworks 4.0 software (UVP Inc., Upland, California).

VI. Preparation of nuclear extracts and EMSA

Gel shift assays were performed according to the manufacturer's recommendations (Promega, Madison, WI). Briefly, 10⁶ cells/ml were washed twice with 1 PBS, followed by the addition of 1 ml of PBS, and the cells were scraped into a cold Eppendorf tube. Cells were spun down at 15,000 g for 1 min, and the resulting supernatant was removed. Solution A (50 mM HEPES, pH 7.4, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.1 g/ml phenylmethylsulfonyl fluoride, 1 g/ml pepstatin A, 1 g/ml leupeptin, 10 g/ml soybean trypsin inhibitor, 10 g/ml aprotinin, and 0.5% Nonidet P-40) was added to the pellet in a 2:1 ratio (v/v) and allowed to incubate on ice for 10 min. Solution C (solution A + 10% glycerol and 400 mM KCl) was added to the pellet in a 2:1 ratio (v/v) and vortexed on ice for 20 min. The cells were centrifuged at 15,000 g for 7 min, and the resulting nuclear extract supernatant was collected in a chilled Eppendorf tube. Consensus oligonucleotides were end-labeled using T4 polynucleotide kinase and [³²P] ATP for 10 min at 37 C. Gel shift reactions were assembled and allowed to incubate at room temperature for 10 min followed by the addition of 1 l (50,000-200,000 cpm) of ³²P-labeled oligonucleotide, and another 20 min of incubation at room temperature. Subsequently 1 l of gel loading buffer was added to each reaction, and loaded onto a 4% non denaturing gel, and then electrophoresed until the dye was three-fourths of the way down the gel. The gel was dried at 80 C for 1 hr and exposed to film overnight at 70 C. The relative density of the protein bands was scanned by

densitometry using MyImage (SLB, Seoul, Korea), and quantified by Labworks 4.0 software (UVP Inc., Upland, California).

VII. Transfection assay

Synoviocyte were transfected with pNF-kB-Luc plasmid (5x NF-kB; Stratagene, CA, USA) using a mixture of plasmid and lipofectamine plus in OPTI-MEN according to manufacture's specification (Invitrogen, Carlsbad, CA, USA). The control pCMV (Clontech, CA, USA) was co-transfected to monitor the transfection efficiency. After 24 hr, the cells were then co-treated with BV (or melittin) and SNP.

VIII. Surface plasmon resonance analysis

Activated CM-dextran matrix carried out by mixing ethyl-N-(dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide was surfaced on the sensor chip. Melittin was then layered onto the CM-dextran sensor chip, and then the chip was blocked by 1M ethanolamine, pH 8.5. Serial dilutions of BV, melittin or immunoprecipitated p50 extracted from nuclear fraction of cells treated by SNP were prepared using HEPES buffered saline buffer, and then flowed sequentially with increasing concentration. The regeneration of protein interaction was performed by changing of the pH of solution and then finally determined by pH12. The BIACORE 2000TM system continuously monitors the change in mass at the sensor surface, and the protein

interaction kinetics were analyzed by BIAevaluation 3.0 software (BIAcore AB, 5-75450, Uppsala, Sweden).

IX. Statistical analysis

Data were analyzed using one-way analysis of variance followed by Tuckey test as a post hoc test. Differences were considered significant at $p < 0.05$.




Fig. 1. Binding Affinity of Be Venom and p50 in Vtro Representative grape of two experiments

X. Results

1. Interaction between p50 and BV or melittin

We studied the interaction between p50 and melittin or BV. Binding ability of the immunoprecipitates against p50 antibodies to melittin immobilized onto a surface of sensor chip was monitored by Biacore analyzer. Increasing dose of immunoprecipitates against p50 antibodies clearly showed increased binding activity with BV or melittin.

The maximum Kd value of binding affinity of p50 with BV or melittin is 4.6×10^{-6} , 1.2×10^{-8} M respectively (fig. 1, fig.2).




Fig. 2. Binding Affinity of Melittin and p50 in Vtro Representative grape of two experiments




Fig. 3. Inhibitory Effect of BV or Melittin on the LPS-induced Release of p-IkB in Synovocytes
*: $P < 0.05$. Statistical significance compared with control

2. Inhibitory effect of BV and melittin on SNP-induced I κ B release

Release of the inhibitory I κ B subunit is involved in activation of NF- κ B. To elucidate the effect of melittin and BV on this step, the kinetics of I κ B release in cytosol were studied by western blot analysis. SNP-induced I κ Bs release was markedly inhibited by melittin and BV in synovocytes (Fig. 3, Fig.4). The inhibitory effect of melittin on release of I κ B was similar to BV. The synergic effect of




Fig. 4. Inhibitory Effect of BV or Melittin on the LPS-induced Release of p-IkB in Synoviocytes Representative photography of three separated experiments with duplicates both is also found.




Fig. 5. Inhibitory Effect of BV and Melittin on the LPS-induced p50-DNA Binding Activity Values are mean±S.D. of three experiments with triplicates

* : P<0.05. Statistical significance compared with control
 Values are mean±S.D. of three experiments with triplicates
 * : P<0.05. Statistical significance compared with control

3. Inhibitory effect of BV and melittin on DNA binding activity

NF-κB DNA binding activity was performed by EMSA in nuclear extracts of synoviocytes treated with SNP alone, or combination with melittin, or BV for 1 hr that was the time to induce NF-κB activation maximally (data not shown). BV and Melittin inhibited NF-κB DNA binding activity by SNP in a dose

dependent manner in synoviocytes (Fig. 5).

4. DTT and GSH reversed inhibitory effect of BV and melittin.

We previously found that BV and melittin bind to p50 subunit of NF-κB and IKK which prevent the release of IκB and the translocation of p50 into nucleus. This Inhibitory effect was reversed by thiol reducing agents such as DTT, GSH and H2O2, suggesting that sulfhydryl group of p50




Fig. 6. Reverse Effect of DTT on the inhibitory Effect of BV and Melittin in the LPS-induced p50-DNA Binding Activity in cultured Synoviocytes Values are mean±S.D. of three experiments with triplicates

* : P<0.05. Statistical significance compared with LPS+BV (or Melittin) treated group




Fig. 7. Reversed inhibitory Effect of BV and Melittin on p-IkB Expression and Synoviocytes after Reducing Agents DTT and GSH Treatment after Treatment by SNP

: P<0.05, Statistical significance compared with normal (p<0.05)
 * : P<0.05, Statistical significance compared with control (SNP treated) group
 □□ : P<0.05, Statistical significance compared with BV or Melittin treated group

may be a target molecule binding to BV and melittin.

To demonstrate this possibility, we first performed DNA binding activity of NF- κ B by EMSA and then did Release of I κ B by western blotting with DTT and GSH in Synoviocyte and found inhibitory effect of BV and melittin on NF- κ B activity(fig.6) and Release of I κ B was reversed by treatment of reducing agents DTT and GSH dose dependently(fig.7)..

The preventive effect of the SNP-induced release of NO was reversed by DTT, GSH and H₂O₂ in proportion to the reversed effect on DNA binding activities of NF- κ B in synoviocytes virtually

5. Abolition of the inhibitory effects of melittin on NO generation in p50 mutant cells

We conducted a transient transfection assay




Fig. 8. Inhibitory Effect of Melittin on the SNP-induced NO Levels and reverse Effect of GSH, DTT and H₂O₂ in Synoviocytes Values are mean±S.D. of three experiments with triplicates

: P<0.05, Statistical significance compared with normal

* : P<0.05, Statistical significance compared with control (SNP treated) group □□ : P<0.05, Statistical significance compared with melittin treated group

with a fusion gene containing NF- κ B-luc plasmid DNA (0.8g), NF- κ B-gal plasmid DNA (0.2g) promoter. Synoviocytes were transfected with these promoter reporter gene constructs. NO was then measured after stimulating the cells by SNP with or without melittin or BV in cell supernatant. Contrast to a significant inhibition of NO generation in the cells transfected vector alone(data not shown), melittin and BV did not inhibit SNP-induced NO generation(fig.8) and iNOS expression (fig.9,10) in the transfected with p50 dominant negative mutants in synoviocytes.




Fig. 9. Reversed inhibitory Effect of Melittin on NO Synthesis in Mutant p50 Plasmid transfected Synoviocytes after Treatment by SNP Values are mean±S.D. of three experiments with triplicates

: P<0.05, Statistical significance compared with wild type of cells




Fig. 10. Reversed inhibitory Effect of Melittin on iNOS Expression in Mutant p50 Plasmid transfected Synoviocytes after Treatment by SNP

XI. Discussion

In the present study, the binding affinity of p50 proteins with BV or melittin immobilized on the chip was much greatly lower in the cells treated with SNP in combination of melittin compared to that in the cells treated by SNP alone. Similar study was reported with the peroxisome proliferators activated receptor gamma agonist 15-deoxy-delta12, 14-prostaglandin J2 (15-deoxy PGJ2) which inhibited IκBa degradation in a way of direct modification IKKa and IKKb molecules⁸⁻⁹. In other study, arsenite, a potent inhibitor of NF-κB activation was showed to interact with a specific cysteine residue (Cys-179) of the IKK catalytic subunits¹⁰, and this interaction was further inhibited by thiol-modifying agents¹¹. The direct interaction between BV or melittin with p50 was evidenced by SPR analysis in the present study. The binding affinity of BV or melittin to p50 is about 4.6×10^{-6} , 1.2×10^{-8} M respectively. The binding affinity of melittin with p50 is much stronger than the binding affinity of other biological protein-protein (receptor) interaction in physiological condition. For examples, estrogen receptor-ligand interaction has affinity about ($K_d = 10^{-2} - 10^{-3}$ M)¹², and the binding affinity of MHC-peptide complex to T cell receptors (TCRs) is about $K_d = 1 \times 10^{-7}$ M¹³. The binding affinity of melittin with p50 is about 1000 times stronger than the binding affinity of MHC-peptide complex to TCRs binding affinity¹⁴. Therefore, our data suggest that the binding of BV or melittin with p50 could directly influence on p50 resulted in inhibition of DNA binding activity of NF-κB and IκB release in physiological condition of body. The inhibitory effect of BV or melittin was associated with suppression of IκBa and

IκBb release through suppression of IKKa and IKKb activation. The promoter region of the murine gene encoding iNOS and COX-2 contains NF-κB binding sites¹⁵. This result therefore shows that the inhibitory effect of inflammatory gene expression could be related with inhibition of DNA binding activity of NF-κB. The inhibitory effect on the IκBa and IκBb activity may be critical mechanism of inactivation of NF-κB by BV or melittin. This notion was supported with the inhibitory effect on IκBa and IκBb release by melittin. Structural data of IKK subunits reveal that cysteine residues are present in the kinase domain of IKKa and IKKb, and some of them located at functionally important sites such as activation of T loop and the catalytic site^{10,16}. We showed that BV or melittin directly binds p50. This data suggest that melittin may modify a sulfhydryl group of p50 protein, thereby hinder IκB release and NF-κB activation. Exogenous addition of a thiol reducing agents; DTT and GSH reversed the melittin-induced inhibition of the DNA binding activity of NF-κB. Furthermore in the presence of H₂O₂, the effect was also reversed supporting this explanation¹¹.

Our data showed that DTT, GSH and H₂O₂ reversed the Inhibitory effect of BV or Melittin on IκB release and DNA binding activity of NF-κB, and that inhibitory effect of BV or melittin on DNA binding activity of NF-κB(p50), iNOS expression and NO generation was abolished in the cells transfected with NF-κB-luc plasmid DNA (0.8g), NF-κB-gal plasmid DNA (0.2g) which cysteine residue replace by alanine.

we think that BV or Melittin might also inhibit IKKa and IKKb activities to release IκB because of their structure with cysteine residue. If this hypothesis were true, BV or melittin could compete with complex protein

involving in multiple step of NF- κ B activation and exert the therapeutic potential of combined inhibition of the prostanoid and nitric oxide synthesis systems by inhibition of IKK and NF- κ B.

XII. References

1. Billingham, M.E., Morley, J., Hanson, J.M., Shipolini, R.A., and Vernon, C.A. Letter: An anti-inflammatory peptide from bee venom. *Nature*. 1973;245: 163-164.
2. Kwon, Y.B., Lee, J.D., Lee, H.J., Han, H.J., Mar, W.C., Kang, S.K., Beitz, A.J., Lee, J.H. Bee venom injection into an acupuncture point reduces arthritis associated edema and nociceptive responses. *Pain* 2001;90:271-280.
3. Perez-Paya, E., Houghten, R.A., and Blondelle, S.E. The role of amphipathicity in the folding, self-association and biological activity of multiple subunit small proteins. *J. Biol. Chem*. 1995;270: 1048-1056.
4. Park, H.J., Lee, S.H., Son, D.J., Oh, K.W., Kim, K.H., Song, H.S., Kim, G. J., Oh, G. T., Yoon, D. Y., and Hong, J. T. Anti-arthritis effect of bee venom: Inhibition of proinflammatory mediator generation by suppression of NF- κ B through interaction with the p50 subunit. *Arthritis Rheum*. 2004;50(11):3504-3515.
5. Stichtenoth, D.O., and Frolich, J.C. Nitric oxide and inflammatory joint diseases. *Br. J. Rheumatol*. 1998; 37: 246-257.
6. Lucas, R., Giannini, C., D'auria, M.V., and Paya, M. Modulatory effect of bolinaquinone, a marine sesquiterpenoid, on acute and chronic inflammatory processes. *J. Pharmacol. Exp Ther*. 2003;304: 172-180.
7. Perkins, D.J., St. Clair, E.W., Misukonis, M.A., and Weinberg, J.B. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). *Arthritis Rheum*. 1998;41: 2205-2210.
8. Wang, C., Fu, M., D'Amico, M., Albanese, C., Zhou, J.N., Brownlee, M., Lisanti, M.P., Chatterjee, V.K., Lazar, M.A., and Pestell, R.G. Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. *Mol. Cell. Biol*. 2001;21: 3057-3070.
9. Cernuda-Morollon, E., Pineda-Molina, E., Canada, F.J., and Perez-Sala, D. 15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. *J. Biol. Chem*. 2001;276: 35530-35536.
10. Kapahi, P., Takahashi, T., Natoli, G., Adams, S.R., Chen, Y., and Tsien, R.Y. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. *J. Biol. Chem*. 2000;275: 36062-36066.
11. Jeon, K.I., Jeong, J.Y., and Jue, D.M. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. *J. Immunol*. 2000;164: 5981-5989.
12. Rich, R.L., Hoth, L.R., Geoghegan, K.F., Brown, T.A., LeMotte, P.K., Simons, S.P., Hensley, P., and Myszka, D.G. Kinetic analysis of estrogen receptor/ligand interactions. *Proc. Natl. Acad. Sci. U. S. A*. 2000;99:8562-8567.
13. Corr, M., Slanetz, A.E., Boyd, L.F., Jelonek, M.T., Khilko, S., al-Ramadi, B.K., Kim, Y.S., Maher, S.E., Bothwell, A.L., Margulies, D.H. T cell receptor-MHC class I peptide interactions: affinity,

- kinetics, and specificity. *Science* 1994;265: 946-949.
14. Lee, J.H., Koo, T.H., Hwang, B.Y., and Lee, J.J. Kaurane diterpene, kamebakaurin, inhibits NF-kappa B by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-kappa B target genes. *J. Biol. Chem.* 2002;277: 18411-18420.
15. Xie, Q.W., Kashiwabara, Y., and Nathan, C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. *J. Biol. Chem.* 1994;269: 4705-4708.
16. Carter, R.S., Geyer, B.C., Xie, M., Acevedo-Suarez, C.A., and Ballard, D.W. Persistent activation of NF-kappa B by the tax transforming protein involves chronic phosphorylation of IkappaB kinase subunits IKKbeta and IKKgamma. *J. Biol. Chem.* 2001; 276:24445-24448.